Review of MARIPOSA Trial: Amivantamab Plus Lazertinib as First-Line Treatment in Patients With <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer

XIE Cong-ying; LIU Jia-qi

doi:10.12019/j.issn.1671-5144.2024.01.004

XIE Cong-ying, LIU Jia-qi. Review of MARIPOSA Trial: Amivantamab Plus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2024, 24(1): 20-25. DOI: 10.12019/j.issn.1671-5144.2024.01.004

Citation:

XIE Cong-ying, LIU Jia-qi. Review of MARIPOSA Trial: Amivantamab Plus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2024, 24(1): 20-25. DOI: 10.12019/j.issn.1671-5144.2024.01.004

Citation:

XIE Cong-ying, LIU Jia-qi. Review of MARIPOSA Trial: Amivantamab Plus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2024, 24(1): 20-25. DOI: 10.12019/j.issn.1671-5144.2024.01.004

Review of MARIPOSA Trial: Amivantamab Plus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Non-Small Cell Lung Cancer

Abstract

FullText(HTML)

References (12)

Review of MARIPOSA Trial: Amivantamab Plus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Non-Small Cell Lung Cancer

Catalog

Export File

Citation

Format

Content